Patents by Inventor Marie-Helene Gouy

Marie-Helene Gouy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists
    Patent number: 10799510
    Abstract: The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: October 13, 2020
    Assignee: Genfit
    Inventors: Maryline Bourotte, Jean-Francois Delhomel, Mathieu Dubernet, Marie-Helene Gouy
  • DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS
    Publication number: 20170296548
    Abstract: The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.
    Type: Application
    Filed: March 6, 2017
    Publication date: October 19, 2017
    Inventors: Maryline Bourotte, Jean-Francois Delhomel, Mathieu Dubernet, Marie-Helene Gouy
  • Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists
    Patent number: 9586963
    Abstract: The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: March 7, 2017
    Assignee: Genfit
    Inventors: Maryline Bourotte, Jean-Francois Delhomel, Mathieu Dubernet, Marie-Helene Gouy
  • DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS
    Publication number: 20150038503
    Abstract: The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.
    Type: Application
    Filed: September 27, 2012
    Publication date: February 5, 2015
    Applicant: GENFIT
    Inventors: Maryline Bourotte, Jean-Francois Delhomel, Mathieu Dubernet, Marie-Helene Gouy